Oxcarbazepine (Epilepsy) updated on 04-22-2025

Small for gestational age (weight)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S16081
R66734		 Christensen (Oxcarbazepine) (Epilepsy) (Controls exposed to LTG), 2024 Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.56 [1.32;1.84] C
excluded (control group) 		222/1,462   546/5,299 768 1,462
ref
S16029
R66538		 Christensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Small for gestational age (a z-score for birth weight ≤10th percentile for gestational week, sex, and country (including newborns with congenital malformations)) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.42 [1.18;1.70] 222/1,462   2,416/22,227 2,638 1,462
ref
S8084
R24700		 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Small for gestational age (birth weight) throughout pregnancy retrospective cohort exposed to other treatment, sick excluded Adjustment: No 7.80 [0.23;262.83] C
excluded (control group) 		1/4   0/7 1 4
ref
S8075
R24640		 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Small for gestational age (birth weight) throughout pregnancy retrospective cohort unexposed, sick Adjustment: No 25.80 [0.81;819.45] C 1/4   0/22 1 4
ref
S7808
R23129		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Small for gestational age (weight) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.00 [0.58;1.74] C 14/143   167,376/1,710,441 167,390 143
ref
S8146
R25048		 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) early pregnancy retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: Yes 1.99 [0.59;6.72]
excluded (control group) 		-/-   -/- - -
ref
S8142
R25020		 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 Small for gestational age (ICD-9 656.5, 764.0, 764.1, 764.9) early pregnancy retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: Yes 1.61 [0.79;3.28] -/-   41,653/1,440,631 - -
ref
Total 4 studies 1.37 [0.99;1.89] 170,029 1,609
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Christensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024Christensen, 2024 1 1.42[1.18; 1.70]2,6381,46260%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Aydin, 2020 2 25.80[0.81; 819.45]141%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 3 1.00[0.58; 1.74]167,39014323%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019Cohen, 2019 4 1.61[0.79; 3.28]--16%ROB confusion: moderateROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 31% 1.37[0.99; 1.89]170,0291,6090.5100.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Epilepsy) (Controls unexposed, general population; 2: Oxcarbazepine) (Controls unexposed, sick; 3: Oxcarbazepine) (Controls unexposed, NOS; 4: Oxcarbazepine) (Controls unexposed NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.37[0.99; 1.89]170,0291,60931%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 4 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.20[0.76; 1.89]167,3901437%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 2 unexposed, sickunexposed, sick 3.54[0.25; 49.71]2,6391,46663%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 2 Tags Adjustment   - No  - No 3.19[0.15; 67.31]167,39114770%NAAydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 2   - Yes  - Yes 1.43[1.20; 1.71]2,6381,4620%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 2 All studiesAll studies 1.37[0.99; 1.89]170,0291,60931%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 40.5100.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.14.52.1170.000Christensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 8146, 8084, 16081

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.20[0.76; 1.89]209,0341437%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Cohen (Oxcarbazepine) (Controls unexposed NOS), 2019 2 unexposed, sick controlsunexposed, sick controls 3.54[0.25; 49.71]2,6391,46663%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls unexposed, general population), 2024 Aydin (Oxcarbazepine) (Controls unexposed, sick), 2020 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.57[1.33; 1.86]7691,4660%NAChristensen (Oxcarbazepine) (Epilepsy) (Controls exposed to LTG), 2024 Aydin (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Cohen (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2019 30.510.01.0